5:33 PM
 | 
Aug 28, 2013
 |  BC Extra  |  Top Story

Astex up on data for second-generation Dacogen

Astex Pharmaceuticals Inc. (NASDAQ:ASTX) added $1.34 (24%) to $6.82 on Wednesday after reporting that subcutaneous once-daily SGI-110 led to an overall remission rate of 25% in 67 evaluable acute myelogenous leukemia (AML) patients in the Phase II portion of the Phase I/II SGI-110-01 trial to treat...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >